Abstract 4417:In vitroefficacy of dasatinib alone or in combination with PARP inhibitor plus standard cytotoxic agent in triple-negative breast cancer cell lines
2016 ◽
2014 ◽
Vol 149
(1)
◽
pp. 81-89
◽
2011 ◽
2016 ◽
2014 ◽